Etira CEO Featured In Clinical Leader for R&D Efficiency

In an article just published in Clinical Leader magazine entitled “How An Australia-First Strategy Cut 63% From Our R&D Spend”, Etira CEO Russell Hayward explains how our strategic decision to conduct clinical trials in Australia has significantly reduced our R&D spending.

This innovative approach enables us to accelerate the development of our first-in-class cancer therapy, ERX-315, and deliver promising new treatments to our patients faster.

Read the full article at https://www.clinicalleader.com/doc/how-an-australia-first-strategy-cut-from-our-r-d-spend-0001